Cann Group says its balance-sheet repair and cost cuts have created room for growth, with September-quarter revenue and exports jumping. But the medicinal cannabis producer remains loss-making on a normalised basis and is now under pressure to turn improving sales into consistently positive cash flow.
- September-quarter revenue of $3.45 million, unaudited
- Exports reached around 40% of quarterly sales
- FY2026 normalised loss narrowed 21% to $14.7 million
- Operating costs fell 34% to $14.7 million
- Non-binding discussions on industry partnering and consolidation
Export Growth Puts Cann Group’s Cash Recovery to the Test
Cann Group Limited (ASX:CAN) has moved from balance-sheet survival to a more demanding test: proving that stronger export sales can produce cash. The September quarter delivered unaudited revenue of $3.45 million, roughly 70% above the average quarterly revenue in the second half of FY2026, while exports rose to about 40% of sales from 16% across the full prior year.
The figures extend the September quarter growth story, which included the same $3.45 million revenue figure and a 23% reduction in inventory. Customer receipts rose 18% in the quarter, costs stayed around the second-half run-rate and inventory fell a further 23%, according to Executive Chairman Mike Ryan’s address to shareholders.
Debt Forgiveness Lifted Profit as Underlying Loss Narrowed
FY2026 produced a statutory profit after tax of $20.6 million, but Cann cautioned shareholders not to treat that as recurring earnings. The result was driven by the settlement of $70.6 million of NAB debt for a $15.3 million cash payment, funded through a new facility and $9.0 million of equity. On a normalised basis, the company lost $14.7 million, although that loss was 21% smaller than the previous year.
The operating reset was more tangible. Operating costs before depreciation fell 34% to $14.7 million, while operating cash outflow improved 86% to $1.3 million. The latest six-month outflow was $0.9 million, compared with $2.9 million in each of the two preceding six-month periods. September itself still recorded a $0.73 million operating outflow, which Cann attributed to the timing of export invoices being raised late in the quarter.
Mildura Facility Becomes the Export Platform
Cann is positioning its Mildura cultivation and GMP manufacturing facility around international pharmaceutical supply rather than competing primarily in Australia’s pressured flower market. About 6,600 square metres is fitted out, with roughly half used in FY2026, leaving capacity to increase production without new capital expenditure. The facility also received an “A1 - good compliance” rating in the Therapeutic Goods Administration’s latest inspection, while its licence is recognised under mutual recognition arrangements with the European Union and United Kingdom.
The strategy carries an important qualification: certification is an entry ticket, not proof of commercial success. Cann says UK sales reached $1.0 million in FY2026, Europe is being developed as a market and Germany is leading demand for EU-GMP-grade supply. The company’s stated priorities are to lift yield and utilisation against forward orders, grow exports and branded products, keep annual costs at or below about $12 million and reach consistently positive operating cash flow.
Cann Group Considers Industry Consolidation
Ryan also used the AGM to argue that the Australian medicinal cannabis sector has more licensed capacity than demand can support. Cann’s presentation cited an October 2026 analysis of 28 listed and private cannabis companies, which it said found cultivation capital earned a negative return in each year. The board is engaging with other industry participants on partnering and consolidation, but no proposal is binding and there is no certainty that a transaction will proceed.
The company says it would only support a combination where the logic is clear and the terms are value-accretive for Cann shareholders. That leaves the immediate investment question less about whether consolidation is fashionable than whether Cann can keep improving receipts, export volume and facility utilisation before another funding requirement becomes necessary.
Bottom Line?
Cann’s reset is beginning to show through in revenue and cash usage, but the next quarters must establish that the September improvement is repeatable rather than timing-driven.
Questions in the middle?
- Can export growth translate into positive operating cash flow after invoice timing normalises?
- How quickly can Mildura’s unused capacity be converted into contracted, profitable production?
- Will any proposed consolidation create value for Cann shareholders, or simply combine underutilised capacity?